JPRN-UMIN000046707已完成未知
Multicenter, retrospective study to assess the safety and efficacy of combination therapy with combination ophthalmic solutions for glaucoma in patients with primary open-angle glaucoma or ocular hypertension - Multicenter, retrospective study to assess the safety and efficacy of combination therapy with combination ophthalmic solutions for glaucoma in patients with primary open-angle glaucoma or ocular hypertension
Yotsuya Shirato Eye Clinic0 个研究点目标入组 45 人开始时间: 2022年1月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients who had been treated by combination therapy with prostaglandin ophthalmic solution and combination ophthalmic solution with carbonic anhydrase inhibitor and beta-blocker for less than 8 weeks before the prescription change. 2) Patients with ocular measurements of less than 15 mmHg on the day of prescription change3) Patients with a history of glaucoma surgery (including laser surgery and cryocoagulation) in the eye subject to efficacy evaluation. 4) Patients who used bimatoprost ophthalmic solution before the prescription change. 5) Patients who used other ophthalmic solutions for glaucoma concomitantly during the observation period after the prescription change. 6) Patients whose medication adherence of combination therapy with latanoprost/carteolol ophthalmic solution and brimonidine/brinzolamide ophthalmic solution in the eye subject to efficacy evaluation was deemed to be poor after the change of prescription according to the medical records 7) Patients who were treated by glaucoma surgery (including laser surgery and cryocoagulation) or any other procedural treatment in the eye subject to efficacy evaluation during the observation period after the prescription change. 8) Patients who used other ophthalmic solutions for glaucoma in combination with prostaglandin ophthalmic solution and carbonic anhydrase inhibitor/beta-blocker combination ophthalmic solution during the period before the prescription change. 9) Patients who are judged by the investigators to be inappropriate for this study based on medical records.
研究者
相似试验
已完成
不适用
A multi-center, open-label study to assess the safety and efficacy of combination ceritinib (LDK378) and nivolumab in adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (CLDK378A2120C)non small cell lung cancer10029107lung cancerNL-OMON44906ovartis3
已完成
不适用
Prospective, multicenter study to evaluate the Safety and performance of a syntHetic tissue sealant in reducing fluid lEakage following elective hepatobiLiary anD pancreatic SurgeryFluid leakage following elective hepatobiliary and pancreatic surgery / leakage of bile and pancreatic juices after surgery10019818NL-OMON55236Polyganics BV, Groningen12
已完成
不适用
Study to investigate the use of REAL INTELLIGENCE™ CORI™ in Knee Replacement SurgeriesCTRI/2021/07/035056Smith and Nephew Inc7
进行中（未招募）
2 期
A multicentre single arm study of carfilzomib-thalidomide-dexamethasone (CarTD) for newly diagnosed transplant-eligible multiple myeloma (MM) patients refractory to initial bortezomib-based induction therapyCancer - MyelomaMultiple MyelomaACTRN12615000934549Australiasian Leukaemia and Lymphoma Group50
招募中
不适用
Evaluation of the Safety & Effectiveness of the PROMUS Element Everolimus-Eluting Coronary Stent System in patients with new or untreated atherosclerotic coronary artery lesionsACTRN12609000724279Boston Scientific Pty Ltd102